Article
Pharmacology & Pharmacy
Walter Schmitt, Hauke Ruehs, Rolf Burghaus, Christian Diedrich, Sulav Duwal, Thomas Eissing, Dirk Garmann, Michaela Meyer, Bart Ploeger, Joerg Lippert
Summary: The study demonstrates that NT-proBNP can serve as a surrogate for clinical outcomes in HF trials, with a well-described relationship between NT-proBNP concentration and clinical events using an E-max model. Quantitative analysis provided insights into potential risks and risks associated with clinical events. Model-based predictions solely based on NT-proBNP measurements match final trial results, and early NT-proBNP measurements enable shorter yet reliable HF trials.
CLINICAL PHARMACOLOGY & THERAPEUTICS
(2021)
Article
Multidisciplinary Sciences
Per M. Arvidsson, Anders Nelsson, Martin Magnusson, J. Gustav Smith, Marcus Carlsson, Hakan Arheden
Summary: Hemodynamic force analysis was investigated as a tool for distinguishing between healthy subjects and heart failure patients with different degrees of systolic dysfunction. Results showed that volume-normalized hemodynamic forces were positively correlated with ejection fraction (EF) and were significantly lower in heart failure with reduced ejection fraction compared to controls. There was no significant difference between controls and heart failure patients with preserved ejection fraction (HFpEF). Non-normalized forces did not show any differences between controls and HFpEF patients and did not correlate with EF. Left ventricular hemodynamic force analysis, regardless of volume normalization, is not ready for clinical trials to assess HFpEF.
SCIENTIFIC REPORTS
(2022)
Article
Cardiac & Cardiovascular Systems
Stefanie M. Werhahn, Christian Becker, Meinhard Mende, Helge Haarmann, Kathleen Nolte, Ulrich Laufs, Samira Zeynalova, Markus Loeffler, Nikolaos Dagres, Daniela Husser, Marcus Doerr, Stefan Gross, Stephan B. Felix, Astrid Petersmann, Christoph Herrmann-Lingen, Lutz Binder, Martin Scherer, Gerd Hasenfuss, Burkert Pieske, Frank Edelmann, Rolf Wachter
Summary: In stable outpatients with cardiovascular risk factors, NT-proBNP is a better marker for prevalent and incident AF than for HF. The diagnostic value of NT-proBNP for HF in AF patients, especially with EF > 50%, is very limited.
Article
Chemistry, Analytical
Maria Antonio, Rui Vitorino, Ana L. Daniel-da-Silva
Summary: We developed a rapid and straightforward localized surface plasmon resonance (LSPR)-based assay for detecting NT-proBNP in urine using citrate-capped gold nanoparticles and an aptamer specific for NT-proBNP. The assay showed linear correlation between NT-proBNP concentration and aggregation ratio, with a detection range of 0.566-8 μg.L-1 and a limit of detection (LOD) of 0.303 μg.L-1. However, the presence of sulfur-containing proteins hindered detection in saliva and fetal bovine serum. Nevertheless, the assay successfully detected NT-proBNP in diluted urine, showing potential clinical relevance. The recovery percentages ranged from 92.3 to 116.3%.
Article
Cardiac & Cardiovascular Systems
Yaoyao Zhou, Qifeng Zhu, Po Hu, Huajun Li, Xinping Lin, Xianbao Liu, Zhaoxia Pu, Jian'an Wang
Summary: This study aimed to investigate the short-term trajectory of NT-proBNP following TAVR and its association with clinical outcomes in TAVR recipients. Three distinct NT-proBNP trajectories were identified, and patients with different trajectories had significantly different risks of all-cause death and cardiac death. These findings highlight the prognostic value of NT-proBNP trajectory in TAVR recipients.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2023)
Article
Cardiac & Cardiovascular Systems
William R. Miranda, C. Charles Jain, Barry A. Borlaug, Allan S. Jaffe, Heidi M. Connolly, Luke J. Burchill, Alexander C. Egbe
Summary: This study found that resting and exercise pressures in the heart and pulmonary artery were correlated with exercise capacity and NT-proBNP levels in adults post-Fontan. Additionally, exercise cardiac catheterization may provide prognostic information.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
(2023)
Article
Cardiac & Cardiovascular Systems
Paul W. Armstrong, Yinggan Zheng, Richard W. Troughton, Lars H. Lund, Jian Zhang, Carolyn S. P. Lam, Cynthia M. Westerhout, Robert O. Blaustein, Javed Butler, Adrian F. Hernandez, Lothar Roessig, Christopher M. O'Connor, Adrian A. Voors, Justin A. Ezekowitz
Summary: This study assessed the effect of vericiguat on changes in NT-proBNP levels and its relationship with clinical outcomes. The results showed that vericiguat treatment led to a significant decline in NT-proBNP levels, which was associated with a relative improvement in the primary outcome of cardiovascular death or heart failure hospitalization.
JACC-HEART FAILURE
(2022)
Article
Cardiac & Cardiovascular Systems
Stefano Ciardullo, Federico Rea, Rosa Cannistraci, Emanuele Muraca, Silvia Perra, Francesca Zerbini, Andrea Mortara, Gianluca Perseghin
Summary: This study found that elevated NT-ProBNP levels were independently associated with all-cause and cardiovascular mortality in the general population, aiding in the identification of high-risk patients.
CARDIOVASCULAR DIABETOLOGY
(2022)
Article
Veterinary Sciences
Diana Rammal, Christos K. K. Koutinas, Labrini V. V. Athanasiou, Melpomeni Tangalidi, Camila P. P. Rubio, Jose J. Ceron, Androniki Tamvakis, Michael N. N. Patsikas, Zoe S. S. Polizopoulou
Summary: The study aimed to measure the concentration of Paraoxonase-1 (PON-1) and N-terminal-prohormone-B-type natriuretic peptide (NT-proBNP) in dogs with mitral valve disease and determine their association with clinical stage and specific clinico-pathologic and echocardiographic findings. The results showed that PON-1 was not correlated with clinical stage, gender, or concurrent conditions. NT-proBNP, on the other hand, was correlated with clinical stage and echocardiographic indices of cardiomegaly and heart failure. These findings suggest that PON-1 is an insensitive marker for the severity of mitral valve disease and its utility may be hindered by confounding factors.
VETERINARY SCIENCES
(2023)
Article
Medical Laboratory Technology
Ling Li, Alexander G. Semenov, Evgeniya E. Feygina, Chenchen Yang, Nan Wang, Chao Chen, Xinghai Hu, Xiaoqin Ni, Zhenlu Zhang
Summary: The study compared the diagnostic accuracy of two NT-proBNP assays and found that the clinical value of total NT-proBNP for HF diagnosis was similar to the non-glycosylated subfraction of NT-proBNP. The lower percentage of non-glycosylated NT-proBNP to total NT-proBNP in non-HF patients suggests that total NT-proBNP might be more sensitive in individuals without current or prior symptoms of HF.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE
(2023)
Article
Anesthesiology
Christian Reiterer, Barbara Kabon, Alexander Taschner, Markus Falkner von Sonnenburg, Alexandra Graf, Nikolas Adamowitsch, Patrick Starlinger, Julius Goshin, Melanie Fraunschiel, Edith Fleischmann
Summary: In a randomized trial involving 260 patients undergoing major abdominal surgery, no significant difference was found in postoperative NT-proBNP concentration and the incidence of MINS between the group receiving 80% oxygen and the group receiving 30% oxygen during and after surgery.
JOURNAL OF CLINICAL ANESTHESIA
(2021)
Article
Medicine, General & Internal
Chin-Shern Lau, Ya Li Liang, Soon Kieng Phua, Gillian Murtagh, Imo E. Hoefer, Ron H. Stokwielder, Milica Kosevich, Jennifer Yen, Jaganathan Sickan, Christos Varounis, Tar-Choon Aw
Summary: This study evaluated the performance of the Abbott NT-proBNP assay compared to the Roche NT-proBNP immunoassay at two sites. Precision, linearity, and sensitivity studies were conducted, and a regression analysis was performed. The results showed excellent agreement between the two assays, with slight bias in the Roche assay. The age groups recommended for acute heart failure diagnosis by ESC/AHA were also applicable to the Abbott assay.
Article
Emergency Medicine
Cecilie Budolfsen, Anders Sjorslev Schmidt, Kasper Glerup Lauridsen, Camilla Bang Hoeks, Farhad Waziri, Christian Bo Poulsen, Dung Nguyen Riis, Hans Rickers, Bo Lofgren
Summary: This study aims to identify the optimal NT-proBNP cut-off value for ruling out heart failure among atrial fibrillation patients. The results showed that NT-proBNP can be used to rule out heart failure in atrial fibrillation patients, but with low specificity.
AMERICAN JOURNAL OF EMERGENCY MEDICINE
(2023)
Article
Veterinary Sciences
Rebekka Mach, Pia Saskia Wiegel, Jan-Peter Bach, Martin Beyerbach, Charanthorn Levicar, Ingo Nolte
Summary: This study investigated the impact of Brachycephalic Obstructive Airway Syndrome (BOAS) on blood pressure and NT-proBNP values in pugs. The results showed no significant association between the severity of BOAS symptoms and measured values. Additionally, excitement and exercise appeared to have a greater influence on the measurements. The study also found that commonly used reference ranges for blood pressure and NT-proBNP are applicable in pugs.
FRONTIERS IN VETERINARY SCIENCE
(2022)
Article
Oncology
Jozef Chovanec Jr, Jozef Chovanec, Michal Chovanec, Michal Mego
Summary: Currently, it is known that cancer cells can produce natriuretic peptides. The synthesis of N-terminal pro B-type natriuretic peptide (NT-proBNP) may be a response to the activity of proinflammatory cytokines. NT-proBNP is also a marker for myocardial damage caused by anthracycline chemotherapy in cancer patients.
Article
Cardiac & Cardiovascular Systems
Eva M. Boorsma, Jozine M. Ter Maaten, Kevin Damman, Bart J. van Essen, Faiez Zannad, Dirk J. van Veldhuisen, Nilesh J. Samani, Kenneth Dickstein, Marco Metra, Gerasimos Filippatos, Chim C. Lang, Leong Ng, Stefan D. Anker, John G. Cleland, Pierpaolo Pellicori, Ron T. Gansevoort, Hiddo J. L. Heerspink, Adriaan A. Voors, Johanna E. Emmens
Summary: Albuminuria is common in patients with heart failure and is associated with clinical symptoms and biomarkers of congestion. It is also related to the severity and prognosis of heart failure.
EUROPEAN HEART JOURNAL
(2023)
Article
Cardiac & Cardiovascular Systems
Joao Pedro Ferreira, John G. Cleland, Nicolas Girerd, Erwan Bozec, Patrick Rossignol, Pierpaolo Pellicori, Franco Cosmi, Beatrice Mariottoni, Scott D. Solomon, Bertram Pitt, Marc A. Pfeffer, Amil M. Shah, Johannes Petutschnigg, Burkert Pieske, Frank Edelmann, Faiez Zannad
Summary: This study used meta-analysis of individual-patient data to find that spironolactone improves cardiac structure and function in patients with heart failure and preserved ejection fraction (HFpEF).
EUROPEAN JOURNAL OF HEART FAILURE
(2023)
Article
Cardiac & Cardiovascular Systems
Wouter Ouwerkerk, Jasper Tromp, John G. F. Cleland, Christiane E. Angermann, Ulf Dahlstrom, Georg Ertl, Mahmoud Hassanein, Sergio Perrone, Mathieu Ghadanfar, Anja Schweizer, Achim Obergfell, Kenneth Dickstein, Gerasimos Filippatos, Sean P. Collins, Carolyn S. P. Lam
Summary: In patients with acute heart failure, delayed administration of intravenous diuretics was not significantly associated with in-hospital mortality, but was associated with increased 30-day mortality, especially in high-risk patients. This association was independent of left ventricular ejection fraction or geographic region.
EUROPEAN JOURNAL OF HEART FAILURE
(2023)
Article
Cardiac & Cardiovascular Systems
Kieran F. Docherty, John J. V. McMurray, Brian L. Claggett, Zi Michael Miao, Kirkwood F. Adams, Alexandra Arias-Mendoza, John G. F. Cleland, Rafael Diaz, Luis E. Echeverria Correa, G. Michael Felker, Candida Fonseca, Jing Li, Marco Metra, Karen Sliwa-Hahnle, Scott D. Solomon, Hans J. Vandekerckhove, Dragos Vinereanu, Adriaan A. Voors, Stephen B. Heitner, Stuart Kupfer, Fady I. Malik, Lisa Meng, John R. Teerlink
Summary: This study aimed to examine the effect of omecamtiv mecarbil in heart failure patients according to the NT-proBNP levels. The results showed that omecamtiv mecarbil had a greater benefit in patients with higher baseline NT-proBNP levels, especially those without atrial fibrillation/flutter.
EUROPEAN JOURNAL OF HEART FAILURE
(2023)
Article
Cardiac & Cardiovascular Systems
Zachary I. Whinnett, Matthew J. Shun-Shin, Mark Tanner, Paul Foley, Badri Chandrasekaran, Philip Moore, Shaumik Adhya, Norman Qureshi, Amal Muthumala, Rebecca Lane, Aldo Rinaldi, Sharad Agarwal, Francisco Leyva, Jonathan Behar, Sukh Bassi, Andre Ng, Paul Scott, Rachana Prasad, Jon Swinburn, Joseph Tomson, Amarjit Sethi, Jaymin Shah, Phang Boon Lim, Andreas Kyriacou, Dewi Thomas, Jenny Chuen, Ravi Kamdar, Prapa Kanagaratnam, Myril Mariveles, Leah Burden, Katherine March, James P. Howard, Ahran Arnold, Pugazhendhi Vijayaraman, Berthold Stegemann, Nicholas Johnson, Emanuela Falaschetti, Darrel P. Francis, John G. F. Cleland, Daniel Keene
Summary: The study evaluated the effects of optimized His bundle pacing compared to no-pacing in patients with heart failure. It was found that His bundle pacing significantly improved quality of life and was preferred by the majority of patients. However, it did not show any significant changes in peak oxygen uptake or left ventricular ejection fraction.
EUROPEAN JOURNAL OF HEART FAILURE
(2023)
Article
Cardiac & Cardiovascular Systems
Joao Pedro Ferreirra, John G. Cleland, Nicolas Girerd, Patrick Rossignol, Pierpaolo Pellicori, Franco Cosmi, Beatrice Mariottoni, Arantxa Gonzalez, Javier Diez, Scott D. Solomon, Brian Claggett, Marc A. Pfeffer, Bertram Pitt, Johannes Petutschnigg, Burkert Pieske, Frank Edelmann, Faiez Zannad
Summary: Spironolactone reduces serum concentrations of PICP in patients with HFpEF, indicating its anti-fibrotic effect.
INTERNATIONAL JOURNAL OF CARDIOLOGY
(2023)
Editorial Material
Cardiac & Cardiovascular Systems
Milton Packer, John G. F. Cleland
JOURNAL OF CARDIAC FAILURE
(2023)
Article
Cardiac & Cardiovascular Systems
Shirley Sze, Pierpaolo Pellicori, Jufen Zhang, Joan Weston, Andrew L. Clark
Summary: This study compared the prognostic value of various commonly-used frailty tools in ambulatory patients with heart failure. The results showed that frailty is strongly associated with adverse outcomes, and the clinical frailty scale (CFS) could provide more accurate predictions of survival compared to other assessment tools.
EUROPEAN HEART JOURNAL-QUALITY OF CARE AND CLINICAL OUTCOMES
(2023)
Article
Cardiac & Cardiovascular Systems
Joao Pedro Ferreira, John G. F. Cleland, Nicolas Girerd, Pierpaolo Pellicori, Mark R. Hazebroek, Job Verdonschot, Timothy J. Collier, Johannes Petutschnigg, Andrew L. Clark, Jan A. Staessen, Stephane Heymans, Patrick Rossignol, Faiez Zannad
Summary: The study investigated the effect of spironolactone on QRS duration in patients with stage B HFpEF. Spironolactone was found to significantly reduce the QRS duration after 9 months of treatment, indicating improved myocardial electrical activation. This effect was not associated with changes in LV mass or volume.
AMERICAN JOURNAL OF CARDIOLOGY
(2023)
Article
Cardiac & Cardiovascular Systems
Antonio Iaconelli, Joe Cuthbert, Syed Kazmi, Pasquale Maffia, Andrew L. Clark, John G. F. Cleland, Pierpaolo Pellicori
Summary: This study found that venous congestion is more closely associated with prognosis in patients with chronic heart failure than pulmonary hypertension.
CLINICAL RESEARCH IN CARDIOLOGY
(2023)
Editorial Material
Cardiac & Cardiovascular Systems
John G. F. Cleland, Pierpaolo Pellicori, Fraser J. Graham
EUROPEAN HEART JOURNAL
(2023)
Editorial Material
Cardiac & Cardiovascular Systems
Inna P. Gladysheva, Ryan D. Sullivan, Pierpaolo Pellicori
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2023)
Editorial Material
Cardiac & Cardiovascular Systems
Joe J. Cuthbert, John G. F. Cleland
CARDIOVASCULAR RESEARCH
(2023)
Article
Cardiac & Cardiovascular Systems
Kashvi Gupta, Ioannis Mastoris, Andrew J. Sauer
HEART FAILURE CLINICS
(2024)
Review
Cardiac & Cardiovascular Systems
Alexander L. Wallner, Salvatore Savona, Rami Kahwash
HEART FAILURE CLINICS
(2024)
Article
Cardiac & Cardiovascular Systems
Muhammad Shahzeb Khan, Anousheh Awais Paracha, Jan Biegus, Rafael de la Espriella, Julio Nunez, Carlos G. Santos-Gallego, Dmitry Yaranov, Marat Fudim
Summary: The increase of preload in heart failure can lead to excessive intracardiac pressures. The reduction of preload can be achieved through pharmacological and nonpharmacological interventions, with nonpharmacological interventions aiming to reduce blood inflow or increase splanchnic vascular blood pooling.
HEART FAILURE CLINICS
(2024)
Article
Cardiac & Cardiovascular Systems
Parin J. Patel, Asim S. Ahmed
HEART FAILURE CLINICS
(2024)
Article
Cardiac & Cardiovascular Systems
Husam M. Salah, Claudia Baratto, Dmitry M. Yaranov, Karl-Philipp Rommel, Satyanarayana Achanta, Sergio Caravita, Vinay Kumar Reddy Vasanthu, Marat Fudim
HEART FAILURE CLINICS
(2024)
Article
Cardiac & Cardiovascular Systems
Gregory R. Jackson, Abhinav Singh
HEART FAILURE CLINICS
(2024)
Review
Cardiac & Cardiovascular Systems
Ronald D. Bass, Joseph Phillips, Jorge Sanz Sanchez, Priti Shah, Stephen Sum, Ron Waksman, Hector M. Garcia-Garcia
Summary: NIRS-derived LCBI is an effective measurement for identifying vulnerable patients and plaques at risk of future adverse events. Patients with an elevated LCBI have higher odds of enduring a future adverse event.
HEART FAILURE CLINICS
(2024)
Article
Cardiac & Cardiovascular Systems
Adam Bland, Eunice Chuah, William Meere, Thomas J. Ford
Summary: CMD is a challenging condition to manage due to its heterogenous pathophysiology, presentation, and response to therapy. Although awareness of CMD is improving, there is a lack of randomized trials for therapy. Invasive assessment of the coronary microcirculation can improve patient-centered outcomes. Beta-blockers are the cornerstone of therapy for CMD angina, and non-pharmacological interventions play a central role in management. Further research is needed to assess the impact of traditional and novel pharmacological therapies on symptoms and clinical events in different CMD endotypes.
HEART FAILURE CLINICS
(2024)
